Explaining the “Patent Dance” for Biosimilars and the Importance of Trade Secrets

In a recent post on the IVI-sponsored Health Affairs featured blog series, Claire Laporte explains why the patent process dispute between biosimilar and branded drug manufacturers is headed all the way to the Supreme Court and why the outcome could influence intellectual property laws and protections for trade secrets. Read the full article here. About the Health [...]